Allosteric inhibitors of mutant IDH1 or IDH2 induce terminal differentiation of the mutant leukemic blasts and provide durable clinical responses in approximately 40% of acute myeloid leukemia (AML) patients with the mutations. However, primary resistance and acquired resistance to the drugs are major clinical issues. To understand the molecular underpinnings of clinical resistance to IDH inhibitors (IDHi), we performed multipronged genomic analyses (DNA sequencing, RNA sequencing and cytosine methylation profiling) in longitudinally collected specimens from 68 IDH1- or IDH2-mutant AML patients treated with the inhibitors. The analysis revealed that leukemia stemness is a major driver of primary resistance to IDHi, whereas selection of mutations in RUNX1/CEBPA or RAS-RTK pathway genes was the main driver of acquired resistance to IDHi, along with BCOR, homologous IDH gene, and TET2. These data suggest that targeting stemness and certain high-risk co-occurring mutations may overcome resistance to IDHi in AML.
Wang, F., Morita, K., DiNardo, C., Furudate, K., Tanaka, T., Yan, Y., Patel, K., MacBeth, K., Wu, B., Liu, G., Frattini, M., Matthews, J., Little, L., Gumbs, C., Song, X., Zhang, J., Thompson, E., Kadia, T., Garcia-Manero, G., Jabbour, E., Ravandi, F., Bhalla, K., Konopleva, M., Kantarjian, H., Futreal, A., Takahashi, K.